Natural History of Hepatitis B E Antigen to Antibody Seroconversion in Patients with Normal Serum Aminotransferase Levels
Overview
Affiliations
Background: Natural history studies of hepatitis B virus infection have shown relapse of hepatitis in 5% to 15% of patients and progression to cirrhosis in 2% to 6% annually. Follow-up of patients beginning at the early phase of infection might provide data with less referral bias than in previous studies.
Methods: Test of liver biochemistry, assessment of virological markers, and ultrasound examinations were performed at regular intervals during the course of hepatitis B e antigen (HBeAg) to antibody (anti-HBe) seroconversion in 240 HBeAg carriers with normal alanine aminotransferase levels at baseline. Factors predictive of cirrhosis were identified by multivariate analysis.
Results: We enrolled 130 men and 110 women. The mean (+/- SD) age at entry was 27.6 +/- 6.2 years. During the HBeAg-positive phase, 29% of patients had alanine aminotransferase levels > or =200 U/L, 3% had bilirubin levels > or =2.0 mg/dL, and 5% had two or more episodes of alanine aminotransferase levels > or =200 U/L. The mean age at anti-HBe seroconversion was 31.3 +/- 7.0 years, with remission of hepatitis in all patients. However, hepatitis recurred in 36 patients (15%), with an annual rate of 2.2%. Thirteen patients (5%) progressed to cirrhosis. The annual incidence of cirrhosis was 0.5%, and the cumulative probability of cirrhosis after 17 years was 12.6%. Age at anti-HBe seroconversion and relapse of hepatitis were independent risk factors for cirrhosis.
Conclusion: The clinical severity of chronic hepatitis B was milder in this cohort than in previous studies. Delayed HBeAg seroconversion and relapse of hepatitis were associated with increased risk of cirrhosis.
Saha S, Schnabl B Expert Rev Gastroenterol Hepatol. 2025; 19(1):53-64.
PMID: 39760535 PMC: 11882407. DOI: 10.1080/17474124.2025.2450707.
Shin H, Choi W, Kim S, Ko Y, Park Y, Park J JHEP Rep. 2024; 6(7):101089.
PMID: 38974365 PMC: 11225842. DOI: 10.1016/j.jhepr.2024.101089.
Barone M, Iannone A, Mezzapesa M, Milella M, Di Gennaro F, Niro G Pathogens. 2023; 12(10).
PMID: 37887714 PMC: 10609832. DOI: 10.3390/pathogens12101198.
de Almeida Ponde R Mol Biol Rep. 2023; 50(8):6435-6443.
PMID: 37326752 DOI: 10.1007/s11033-023-08546-7.
Current and novel modalities for management of chronic hepatitis B infection.
Ibrahim Salama I, Sami S, Salama S, Abdel-Latif G, Shaaban F, Fouad W World J Hepatol. 2023; 15(5):585-608.
PMID: 37305370 PMC: 10251278. DOI: 10.4254/wjh.v15.i5.585.